Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices-Reference-Cited by-同舟云学术

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices

Published:2017-01-16 Issue:8 Volume:58 Page:1968-1972
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Skarbnik Alan P.¹,Ma Esprit²,Lafeuille Marie-Hélène³,Fortier Jonathan³,Feldman Tatyana¹,Duh Mei Sheng⁴,van de Velde Helgi²,Niculescu Liviu²,Bonthapally Vijayveer²,Goy André¹

Affiliation:

1. Lymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA;

2. Millennium Pharmaceuticals Inc, Cambridge, MA, USA;

3. Groupe d’analyse, Ltée, Montreal, QC, Canada;

4. Analysis Group, Inc, Boston, MA, USA

Funder

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Janssen Global Services, LLC

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1272688

Reference20 articles.

1. Non-Hodgkin’s Lymphomas, Version 4.2014

2. Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management

3. Emerging Therapy for the Treatment of Mantle Cell Lymphoma

4. Transplantation for mantle cell lymphoma: is it the right thing to do?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review;Journal of Blood Medicine;2024-05

2. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

3. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review;Frontiers in Oncology;2023-02-07

4. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States;Journal of Medical Economics;2021-01-01